CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide therapy (TRNT) has emerged as a promising treatment op...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D’Huyvetter, Nick Devoogdt
Format: article
Language:EN
Published: Taylor & Francis Group 2021
Subjects:
multiple myeloma
targeted radionuclide therapy
single domain antibody
cs1
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/5404affaa4564fd0a2b226d2759b274c
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/5404affaa4564fd0a2b226d2759b274c

Similar Items